Cronos Group (CRON) Stock Forecast and Price Target (2026)
Last updated July 2026
Short answer
There is no meaningful analyst consensus for Cronos Group (CRON): too few analysts publish estimates on it for an average target to mean anything. That is normal for smaller and newer companies and says nothing about the business. What is left is the setup, the drivers and the risks below, which you assess yourself rather than starting from someone else's model. Walnut is not an investment adviser.
Why CRON has no consensus price target
Sell-side coverage follows trading volume and banking relationships, so smaller companies, recent listings, and names outside the major indices often carry little or none. That is the situation with CRON. It says nothing about the quality of the business, but it does mean there is no informed average to anchor to, and that any single target you find elsewhere is one analyst's model rather than a consensus.
These figures are approximate, tied to the asOf date, and drawn from 2025 into 2026 reporting; verify live numbers before acting. For a cash-heavy, small-revenue cannabis name, standard earnings multiples are of limited use because so much of the value sits in cash and in an option on policy change rather than in current profits. Compare the market cap to net cash and watch capital allocation as closely as revenue.
Is there a 2030 forecast for CRON?
Not a published one. Analyst price targets run to about twelve months, occasionally two years, and the firms covering CRON do not put out a 2030 number. Anything presenting one is extrapolating a growth rate rather than reporting research, and a figure produced that way tells you about the assumption chosen, not about the company.
What can be said over a long horizon is what the current price already assumes about the business, which is a question the filings answer and a forecast cannot.
That is the more useful frame for a ten-year question. A share price is the market’s estimate of future cash flows discounted to today, so the multiple is already a statement about growth. The long-horizon question is whether Cronos Group can deliver what is priced in, and what would have to change for that to break. Both are answerable from the drivers and risks below. A number for 2030 is not.
What could move CRON from here
In short: the drivers cited most often are Fortress balance sheet and Altria backing, Brand-led, asset-light model, International medical and adult-use expansion. The risk cited most often against it is the biggest risk is regulatory: cannabis remains federally illegal in the US, and reform timelines (rescheduling, SAFE banking, legalization) have slipped repeatedly, so much of the bull case depends on events Cronos cannot control.
Both sides are worked through properly, with the high and low targets used as the bull and bear anchors, on the CRON is it a buy page. This page deliberately stops at the numbers.
Investing in Cronos Group with AI
Connect the broker you already use and ask Walnut's AI how CRON fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the price target for Cronos Group (CRON)?
+
There is no meaningful consensus price target for CRON, because too few analysts publish on it. That is common for smaller and newer companies. Where only one or two analysts cover a stock, an "average target" is really one person's model, so we do not print a number that would imply more agreement than exists. Check your broker's research tab for whatever individual coverage exists.
Why does CRON have no analyst forecast?
+
Sell-side coverage follows trading volume and banking relationships, so small caps, recent listings, and companies outside the major indices often carry little or none. A lack of coverage says nothing about the business itself. It does mean you are doing the analysis yourself rather than starting from someone else's model.
What could move CRON?
+
The drivers and the risks are laid out on this page and in more depth on the CRON "is it a buy" page. Without analyst estimates to anchor to, the honest framing is scenarios rather than a number.
Walnut is informational, not investment advice, and does not publish price targets of its own. The analyst figures on this page come from a September 2026 data pull of published third-party research, are approximate, and change constantly. Verify current figures with your broker before acting on them.
Guides that feature CRON
CRON is one of the names covered in these guides. Each one puts the stock next to its peers so you can see where it fits rather than judging it alone.